Kendell M. Pawelec, Jeremy M. L. Hix, Matti Kiupel, Peter J. Bonitatibus Jr., Erik M. Shapiro
{"title":"Hydrophilic Particles Exit While Hydrophobic Particles Persist Following In Vivo Biodegradation of Nanoparticle-Laden Polymeric Devices","authors":"Kendell M. Pawelec, Jeremy M. L. Hix, Matti Kiupel, Peter J. Bonitatibus Jr., Erik M. Shapiro","doi":"10.1002/anbr.202500005","DOIUrl":null,"url":null,"abstract":"<p>\nLongitudinally monitoring biomedical devices postimplantation can improve patient outcomes by allowing targeted intervention during healing. Most polymeric devices are not visible via biomedical imaging technologies. Incorporation of nanoparticle contrast agents into polymer matrices creates imageable devices, but understanding and controlling nanoparticle clearance from the implant site after polymer degradation is needed for clinical translation. To achieve homogeneous distribution throughout biomedical devices, nanoparticle surface chemistry, particularly hydrophobicity, is often manipulated to generate stable suspensions during manufacture. As nanoparticle surface chemistry is a key parameter determining blood circulation, the effects of nanoparticle hydrophilicity on tissue clearance of nanoparticles from implant sites following polymeric device degradation are investigated. Hydrophilic and hydrophobic radiopaque tantalum oxide (TaO<sub><i>x</i></sub>) nanoparticles are incorporated at 10 wt% tantalum into gelatin phantoms. In vitro, the diffusion coefficient of released hydrophilic nanoparticles after phantom degradation is significantly greater than hydrophobic nanoparticles, 1.29 ± 0.26 × 10<sup>−5</sup> and 0.40 ± 0.16 × 10<sup>−5 </sup>cm<sup>2 </sup>s<sup>−1</sup>, respectively. After subcutaneous implantation in mouse and subsequent phantom degradation, hydrophilic nanoparticles clear skin and muscle tissue within 24 h, whereas hydrophobic nanoparticles remained at the implant site >14 days without change in radiopacity. This clearly demonstrates that nanoparticle surface chemistry must be balanced for initial device manufacturing and final excretion.</p>","PeriodicalId":29975,"journal":{"name":"Advanced Nanobiomed Research","volume":"5 6","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/anbr.202500005","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Nanobiomed Research","FirstCategoryId":"1085","ListUrlMain":"https://advanced.onlinelibrary.wiley.com/doi/10.1002/anbr.202500005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0
Abstract
Longitudinally monitoring biomedical devices postimplantation can improve patient outcomes by allowing targeted intervention during healing. Most polymeric devices are not visible via biomedical imaging technologies. Incorporation of nanoparticle contrast agents into polymer matrices creates imageable devices, but understanding and controlling nanoparticle clearance from the implant site after polymer degradation is needed for clinical translation. To achieve homogeneous distribution throughout biomedical devices, nanoparticle surface chemistry, particularly hydrophobicity, is often manipulated to generate stable suspensions during manufacture. As nanoparticle surface chemistry is a key parameter determining blood circulation, the effects of nanoparticle hydrophilicity on tissue clearance of nanoparticles from implant sites following polymeric device degradation are investigated. Hydrophilic and hydrophobic radiopaque tantalum oxide (TaOx) nanoparticles are incorporated at 10 wt% tantalum into gelatin phantoms. In vitro, the diffusion coefficient of released hydrophilic nanoparticles after phantom degradation is significantly greater than hydrophobic nanoparticles, 1.29 ± 0.26 × 10−5 and 0.40 ± 0.16 × 10−5 cm2 s−1, respectively. After subcutaneous implantation in mouse and subsequent phantom degradation, hydrophilic nanoparticles clear skin and muscle tissue within 24 h, whereas hydrophobic nanoparticles remained at the implant site >14 days without change in radiopacity. This clearly demonstrates that nanoparticle surface chemistry must be balanced for initial device manufacturing and final excretion.
期刊介绍:
Advanced NanoBiomed Research will provide an Open Access home for cutting-edge nanomedicine, bioengineering and biomaterials research aimed at improving human health. The journal will capture a broad spectrum of research from increasingly multi- and interdisciplinary fields of the traditional areas of biomedicine, bioengineering and health-related materials science as well as precision and personalized medicine, drug delivery, and artificial intelligence-driven health science.
The scope of Advanced NanoBiomed Research will cover the following key subject areas:
▪ Nanomedicine and nanotechnology, with applications in drug and gene delivery, diagnostics, theranostics, photothermal and photodynamic therapy and multimodal imaging.
▪ Biomaterials, including hydrogels, 2D materials, biopolymers, composites, biodegradable materials, biohybrids and biomimetics (such as artificial cells, exosomes and extracellular vesicles), as well as all organic and inorganic materials for biomedical applications.
▪ Biointerfaces, such as anti-microbial surfaces and coatings, as well as interfaces for cellular engineering, immunoengineering and 3D cell culture.
▪ Biofabrication including (bio)inks and technologies, towards generation of functional tissues and organs.
▪ Tissue engineering and regenerative medicine, including scaffolds and scaffold-free approaches, for bone, ligament, muscle, skin, neural, cardiac tissue engineering and tissue vascularization.
▪ Devices for healthcare applications, disease modelling and treatment, such as diagnostics, lab-on-a-chip, organs-on-a-chip, bioMEMS, bioelectronics, wearables, actuators, soft robotics, and intelligent drug delivery systems.
with a strong focus on applications of these fields, from bench-to-bedside, for treatment of all diseases and disorders, such as infectious, autoimmune, cardiovascular and metabolic diseases, neurological disorders and cancer; including pharmacology and toxicology studies.